Lupin has been granted a patent for substituted bicyclic heterocyclic compounds that target the overexpression of the PRMT5 enzyme, particularly in cancer treatment. The method involves administering these compounds to inhibit the enzyme and treat associated diseases. GlobalData’s report on Lupin gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Lupin, Cancer treatment biomarkers was a key innovation area identified from patents. Lupin's grant share as of May 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11952380B2) discloses a method for treating various diseases, disorders, syndromes, or conditions associated with the inhibition of the PRMT5 enzyme, particularly cancer. The method involves administering a compound of formula (I), its stereoisomer, or a pharmaceutically acceptable salt to a subject in need. The diseases targeted include glioblastoma multiforme, prostate cancer, pancreatic cancer, mantle cell lymphoma, non-Hodgkin's lymphomas, acute myeloid leukemia, and various other types of cancers such as breast cancer, lung cancer, colorectal cancer, and melanoma.
Furthermore, the patent claims specify the chemical structures of the compounds used in the method, including Formula (II), Formula (III), and Formula (IV), along with various stereoisomers and pharmaceutically acceptable salts. The compounds listed in the claims exhibit specific structural characteristics and are designed to target the PRMT5 enzyme for the treatment of cancer, including lymphocytic leukemia. The patent highlights the potential therapeutic applications of these compounds in addressing a range of cancer types, emphasizing the importance of inhibiting the PRMT5 enzyme in disease management.
To know more about GlobalData’s detailed insights on Lupin, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
